Selective Targeting and Eradication of Various Human Non-Small Cell Lung Cancer Cell Lines Using Self-Assembled...

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Oncology

Background:

• Lung cancer (LC), particularly non-small cell lung cancer (NSCLC), is a leading cause of cancer mortality.
• Current chemotherapy for NSCLC has limited response rates and significant toxicity.
• Targeted nanomedicine offers a promising approach for improving NSCLC treatment efficacy.

Purpose of the Study:

• To investigate the binding and internalization of S15-aptamer (S15-APT)-decorated polyethylene glycol-polycaprolactone (PEG-PCL) nanoparticles (NPs) in various human NSCLC cell lines.
• To evaluate the correlation between NP uptake and the cytotoxicity of paclitaxel-loaded NPs in different NSCLC subtypes.
• To assess the potential of S15-APT-targeted NPs for precision nanomedicine in NSCLC.

Main Methods:

• Synthesis and characterization of S15-APT-decorated PEG-PCL nanoparticles (NPs).
• Confocal microscopy and flow cytometry to assess NP binding and internalization in NSCLC cell lines (A549, H2228, H1299, H522, H1975).
• Cytotoxicity assays using paclitaxel-loaded NPs to determine IC50 values in NSCLC cell lines.

Main Results:

• S15-APT-decorated NPs successfully targeted all tested NSCLC cell lines.
• Variable binding and internalization levels were observed across NSCLC cell lines, with A549 cells showing the highest uptake.
• Cytotoxicity of paclitaxel-loaded NPs correlated with NP uptake, with A549 cells exhibiting the lowest IC50 value.

Conclusions:

• The study demonstrates variable expression of the S15 target receptor across NSCLC cell lines, influencing NP binding and internalization.
• S15-APT-targeted NPs show potential for precision nanomedicine applications in NSCLC.
• These findings support the development of personalized nanomedicine strategies for individual NSCLC patients.